22/01/2010
print this
article | 
email article to a friend
Following recommendations from the European Medicines Agency, the MHRA is suspending the use of the anti-obesity drug sibutramine in the UK after new evidence linked the drug with an increased risk of non-fatal heart attacks and strokes.Full article
Link:
http://www.bioscinews.co.uk/article.aspx?articleid=1876
BioSci Contact:
Jo Thurston
News Source:
Categories:
Endocrinology
|